Related Experiment Video
Updated: Jul 16, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Signaling through RAS-RAF-MEK-ERK: from basics to bedside
Armin Zebisch1, Armin P Czernilofsky, György Keri
1Division of Hematology, Medical University of Graz, Graz, Austria.
Current Medicinal Chemistry
|March 10, 2007
Summary
Aberrant RAS-RAF-MEK-ERK pathway signaling drives cancer. This review explores therapeutic strategies targeting this pathway, focusing on hematological cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- Mutations in the RAS-RAF-MEK-ERK pathway are key drivers of human tumor development.
- Targeting hyperactive signaling molecules presents therapeutic potential but faces clinical translation challenges.
- Understanding pathway crosstalk and regulation is crucial for effective therapeutic strategies.
Purpose of the Study:
- To review the structure, function, and regulation of the RAS-RAF-MEK-ERK signaling cascade.
- To discuss current and emerging therapeutic strategies for interfering with aberrant signaling in cancer.
- To examine signal transduction therapies in the context of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Main Methods:
- Genetic and biochemical approaches to elucidate signaling pathways.
- Review of existing literature on signal transduction and cancer therapy.
- Exemplary discussion of therapeutic strategies in specific hematological malignancies.
Main Results:
- Aberrant signaling in the RAS-RAF-MEK-ERK pathway is a critical factor in tumorigenesis.
- Various strategies exist to inhibit hyperactive signaling molecules, though clinical success is variable.
- Understanding pathway dynamics is essential for optimizing therapeutic interventions.
Conclusions:
- Further research into tumor stem cells, their signaling, and epigenetic changes is vital for advancing novel therapeutic strategies.
- Targeting the RAS-RAF-MEK-ERK pathway offers promise for cancer treatment, particularly in AML and MDS.
- Comprehensive understanding of intracellular signaling is key to overcoming therapeutic setbacks.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...